Co-Diagnostics Current Liabilities
The Current Liabilities of Co-Diagnostics (CODX) as of Oct 8, 2026 is 3.52 M USD. In the previous year, Current Liabilities was 10.79 M USD — a change of -67.34% (lower).
Get this data via API
Financial Data API
Current Liabilities
3.52 MUSD
YoY
-67.34%
Last updated:
The Co-Diagnostics Current Liabilities history
3 Years
10 Years
25 Years
Max
| YEAR | Current Liabilities | YoY |
|---|---|---|
| 3.52 MUSD | -67.34% | |
| 10.79 MUSD | +39.50% | |
| 7.74 MUSD | +52.51% | |
| 5.07 MUSD | -74.89% | |
| 20.21 MUSD | +199.03% | |
| 6.76 MUSD | +978.19% | |
| 626,747.00USD | -86.23% | |
| 4.55 MUSD | +456.84% | |
| 817,464.00USD | -89.17% | |
| 7.55 MUSD | +298.23% | |
| 1.89 MUSD | +1,463.08% | |
| 121,217.00USD | — |
Co-Diagnostics Stock analysis
Frequently Asked Questions about Co-Diagnostics stock
Current Liabilities of Co-Diagnostics is 3.52 M USD in 2025.
Current Liabilities of Co-Diagnostics changed from 10.79 M USD to 3.52 M USD, representing a -67.34% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of Current Liabilities Co-Diagnostics since 2006 – with annual values, charts, and detailed analysis.
Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.
Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Co-Diagnostics historically and in real time.
Balance Sheet — Co-Diagnostics
All Key Metrics — Co-Diagnostics
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth